About Ironwood Pharma
Ironwood Pharma is a company based in Cambridge (United States) founded in 1998.. Ironwood Pharma has raised $206.25 million across 8 funding rounds from investors including Morgan Stanley, Ridgeback Capital Management and Invus. The company has 253 employees as of December 31, 2024. Ironwood Pharma has completed 1 acquisition, including VectivBio. Ironwood Pharma offers products and services including LINZESS. Ironwood Pharma operates in a competitive market with competitors including RedHill Biopharma, Alcresta, Seed, Ardelyx and Norgine, among others.
- Headquarter Cambridge, United States
- Employees 253 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ironwood Pharmaceuticals, Inc.
-
Annual Revenue
$351.41 M-20.63as on Dec 31, 2024
-
Net Profit
$880 K100.09as on Dec 31, 2024
-
EBITDA
$97.73 M-53.6as on Dec 31, 2024
-
Total Equity Funding
$206.25 M (USD)
in 8 rounds
-
Latest Funding Round
$341 M (USD), Post-IPO
Aug 12, 2019
-
Investors
Morgan Stanley
& 8 more
-
Employee Count
253
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Ironwood Pharma
Ironwood Pharma is a publicly listed company on the NASDAQ with ticker symbol IRWD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Ironwood Pharma
Ironwood Pharma offers a comprehensive portfolio of products and services, including LINZESS. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Medication for treating gastrointestinal diseases and symptoms.
Unlock access to complete
Unlock access to complete
Funding Insights of Ironwood Pharma
Ironwood Pharma has successfully raised a total of $206.25M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $341 million completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Post-IPO — $341.0M
-
First Round
First Round
(03 Apr 2002)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2019 | Amount | Post-IPO - Ironwood Pharma | Valuation |
investors |
|
| Nov, 2009 | Amount | Series F - Ironwood Pharma | Valuation |
investors |
|
| Sep, 2009 | Amount | Series F - Ironwood Pharma | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ironwood Pharma
Ironwood Pharma has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Morgan Stanley, Ridgeback Capital Management and Invus. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Long-term private equity investments in transformational opportunities are pursued.
|
Founded Year | Domain | Location | |
|
Government-backed investments are directed toward healthcare, fintech, and various sectors.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on tech sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ironwood Pharma
Ironwood Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include VectivBio. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Transformative therapeutics for rare diseases are developed.
|
2019 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Ironwood Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ironwood Pharma Comparisons
Competitors of Ironwood Pharma
Ironwood Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as RedHill Biopharma, Alcresta, Seed, Ardelyx and Norgine, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases
|
|
| domain | founded_year | HQ Location |
Enzyme-based products for gastrointestinal disorders are developed using immobilization technology.
|
|
| domain | founded_year | HQ Location |
Synbiotics are developed for simulating the gut microbiome.
|
|
| domain | founded_year | HQ Location |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Proprietary therapeutic products for gastrointestinal diseases are developed and marketed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ironwood Pharma
Frequently Asked Questions about Ironwood Pharma
When was Ironwood Pharma founded?
Ironwood Pharma was founded in 1998 and raised its 1st funding round 4 years after it was founded.
Where is Ironwood Pharma located?
Ironwood Pharma is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Ironwood Pharma?
Thomas Mccourt is the current CEO of Ironwood Pharma.
Is Ironwood Pharma a funded company?
Ironwood Pharma is a funded company, having raised a total of $206.25M across 8 funding rounds to date. The company's 1st funding round was a Series F of $25M, raised on Apr 03, 2002.
How many employees does Ironwood Pharma have?
As of Dec 31, 2024, the latest employee count at Ironwood Pharma is 253.
What is the annual revenue of Ironwood Pharma?
Annual revenue of Ironwood Pharma is $351.41M as on Dec 31, 2024.
What does Ironwood Pharma do?
Ironwood Pharma was founded in 1998 in Cambridge, United States, within the pharmaceutical sector. Focus is placed on developing treatments for gastrointestinal conditions. Linaclotide, the lead product, acts as a guanylate cyclase-C agonist and is approved for irritable bowel syndrome with constipation as well as chronic idiopathic constipation. Provisions for pediatric gastrointestinal diseases are also included in the portfolio.
Who are the top competitors of Ironwood Pharma?
Ironwood Pharma's top competitors include Ardelyx, RedHill Biopharma and Seed.
What products or services does Ironwood Pharma offer?
Ironwood Pharma offers LINZESS.
Is Ironwood Pharma publicly traded?
Yes, Ironwood Pharma is publicly traded on NASDAQ under the ticker symbol IRWD.
How many acquisitions has Ironwood Pharma made?
Ironwood Pharma has made 1 acquisition, including VectivBio.
Who are Ironwood Pharma's investors?
Ironwood Pharma has 9 investors. Key investors include Morgan Stanley, Ridgeback Capital Management, Invus, EDBI, and Venrock.
What is Ironwood Pharma's ticker symbol?
The ticker symbol of Ironwood Pharma is IRWD on NASDAQ.